Scientists manage to restrict epilepsy in mice

Image
IANS San Francisco
Last Updated : May 07 2013 | 2:50 PM IST

US scientists have successfully managed to restrict epilepsy in mice that failed to respond to drugs, through transplantation of a particular group of cells, says a study.

Epilepsy that does not respond to drugs can be halted in adult mice by transplanting a specific type of cell into the brain, University of California - San Francisco researchers have discovered, raising hope that a similar treatment might work in severe forms of human epilepsy.

The UC-SF scientists controlled seizures in epileptic mice with a one-time transplantation of medial ganglionic eminence (MGE) cells, which inhibit signalling in overactive nerve circuits into the hippocampus, a brain region associated with seizures, as well as with learning and memory.

Other researchers had previously used different cell types in rodent cell transplantation experiments and failed to stop seizures, reports Science Daily.

Cell therapy has become an active focus of epilepsy research, in part because current medications, even when effective, only control symptoms and not underlying causes of the disease, according to Scott C. Baraban, who led the new study. In many types of epilepsy, he said, current drugs have no therapeutic value at all.

"Our results are an encouraging step toward using inhibitory neurons for cell transplantation in adults with severe forms of epilepsy," Baraban said. "This procedure offers the possibility of controlling seizures and rescuing cognitive deficits in these patients."

The findings, which are the first ever to report stopping seizures in mouse models of adult human epilepsy, were published online May 5 in the journal Nature Neuroscience.

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: May 07 2013 | 2:40 PM IST

Next Story